Arcus Biosciences, Inc. (RCUS)
Largest Insider Buys in Sector
RCUS Stock Price History Chart
RCUS Stock Performance
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in …
Insider Activity of Arcus Biosciences, Inc.
Over the last 12 months, insiders at Arcus Biosciences, Inc. have bought $320M and sold $2.75M worth of Arcus Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Arcus Biosciences, Inc. have bought $140.4M and sold $2.99M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $1.28B.
The last purchase of 15,238,095 shares for transaction amount of $320M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑01‑29.
List of Insider Buy and Sell Transactions, Arcus Biosciences, Inc.
| 2024-08-13 | Sale | Chief Accounting Officer | 1,357 0.0015% | $14.97 | $20,314 | 0.00% | ||
| 2024-03-27 | Sale | Chief Operating Officer | 11,551 0.0123% | $17.55 | $202,720 | -11.07% | ||
| 2024-03-18 | Sale | Chief Operating Officer | 13,449 0.0154% | $17.92 | $240,941 | -5.46% | ||
| 2024-02-27 | Sale | President | 23,132 0.0255% | $20.10 | $464,953 | -18.38% | ||
| 2024-02-27 | Sale | Chief Operating Officer | 34,070 0.0376% | $20.11 | $685,148 | -18.38% | ||
| 2024-02-26 | Sale | President | 3,900 0.0044% | $20.06 | $78,234 | -16.20% | ||
| 2024-02-26 | Sale | Chief Operating Officer | 24,555 0.0276% | $20.07 | $492,819 | -16.20% | ||
| 2024-01-29 | 10 percent owner | 15.24M 28.0689% | $21.00 | $320M | +7.64% | |||
| 2024-01-02 | Sale | President | 6,975 0.0096% | $20.09 | $140,128 | -15.96% | ||
| 2024-01-02 | Sale | Chief Financial Officer | 2,004 0.0027% | $20.00 | $40,080 | -15.96% | ||
| 2023-12-22 | Sale | Chief Operating Officer | 21,521 0.028% | $17.76 | $382,213 | -9.78% | ||
| 2023-12-01 | Sale | Chief Accounting Officer | 282 0.0004% | $14.95 | $4,216 | +2.94% | ||
| 2023-09-22 | Sale | Chief Operating Officer | 21,369 0.0291% | $19.99 | $427,166 | -17.33% | ||
| 2023-07-28 | Sale | Chief Operating Officer | 45,000 0.0639% | $20.25 | $911,250 | -16.91% | ||
| 2023-07-03 | Sale | Chief Accounting Officer | 1,018 0.0014% | $20.41 | $20,777 | -17.18% | ||
| 2023-06-28 | 10 percent owner | 1.01M 1.3257% | $19.26 | $19.45M | -15.57% | |||
| 2023-06-22 | Sale | Chief Operating Officer | 12,437 0.0169% | $19.12 | $237,795 | -11.36% | ||
| 2023-06-16 | Sale | Chief Operating Officer | 12,563 0.017% | $19.35 | $243,094 | -11.87% | ||
| 2023-06-07 | Sale | Chief Financial Officer | 4,049 0.0054% | $20.04 | $81,142 | -15.94% | ||
| 2023-03-16 | Sale | Chief Operating Officer | 8,729 0.0119% | $16.81 | $146,734 | +7.46% |
Insider Historical Profitability
| GILEAD SCIENCES, INC. | 10 percent owner | 30061124 32.8797% | $15.83 | 3 | 0 | <0.0001% |
| Jaen Juan C. | President | 1188233 1.2996% | $15.83 | 8 | 9 | <0.0001% |
| Goeltz II Robert C. | Chief Financial Officer | 51831 0.0567% | $15.83 | 1 | 5 | +33.11% |
| ROSEN TERRY J | Chief Executive Officer | 242173 0.2649% | $15.83 | 21 | 6 | <0.0001% |
| FALBERG KATHRYN E | director | 102106 0.1117% | $15.83 | 7 | 0 | +8.71% |
Institutional Investor Ownership
| BlackRock | $186.92M | 10.89 | 9.9M | -1.34% | -$2.55M | <0.01 | |
| State Street | $92.6M | 5.39 | 4.9M | +15.68% | +$12.55M | <0.01 | |
| The Vanguard Group | $90.46M | 5.27 | 4.79M | +2.36% | +$2.09M | <0.01 | |
| Fidelity Investments | $90.23M | 5.26 | 4.78M | +1.07% | +$953,194.56 | 0.01 | |
| Woodline Partners LP | $54.44M | 3.17 | 2.88M | +178% | +$34.86M | 0.47 |